Dean Rudge

Dean Rudge

Deputy Editor

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest from Dean Rudge

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

Kabi Lines Up Denosumab Biosimilar Launch As FDA Says Yes To Filings

Fresenius Kabi has met its end of the bargain to launch biosimilars to Prolia/Xgeva in the middle of this year, after bagging FDA approvals. The German firm is also set to hear back on its filings in Europe imminently.

AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025

With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.

Cipla Becomes Formosa’s Latest Clobetasol Partner With 11-Country Deal

Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.

Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO

Months on from penning a landmark commercial and manufacturing agreement for GLP-1 assets with Metsera, Amneal says it is happy with how the partnership is shaping up.